Clingen

Quick links to important sections

Clingen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clingen

Property Description
Active Ingredient Clindamycin and Clotrimazole
Form Vaginal Suppository or Vaginal Capsule
Pharmacological Class Anti-infective combination (Lincosamide antibiotic / Imidazole antifungal)
Common Use Management of localized mixed bacterial and fungal infections
Origin Semisynthetic (Clindamycin) and Synthetic (Clotrimazole)

Defining Clingen: A Combination Anti-infective

Clingen is a specialized combination medicine formulated as a Vaginal Suppository or Vaginal Capsule designed for topical, localized intravaginal administration. Its core identity rests on two distinct Active Ingredients: the antibiotic Clindamycin and the antifungal Clotrimazole. This particular dual formulation is used in clinical settings to address infections where multiple types of pathogens are suspected.

The formulation strategically brings together these two chemical entities to address localized infections with a dual approach. Clindamycin is a semisynthetic antibiotic belonging to the Lincosamide class. Clotrimazole is a synthetic compound categorized as an Imidazole antifungal. This combined inclusion of anti-bacterial and anti-mycotic agents makes the product uniquely suited for infections that require simultaneous management of both components, offering comprehensive coverage in a single delivery system.


What Type of Medication is Clingen? (Pharmacological Class)

Clingen is classified as an Anti-infective combination because it merges two different high-level pharmacological classes into a single product. Its components perform separate functions: Clindamycin is a Lincosamide antibiotic, and Clotrimazole is an Imidazole antifungal. The combination of these two agents is intended to provide broad-spectrum activity against common susceptible micro-organisms.

The distinction between these two components defines the medicine's broad utility. Clindamycin works by inhibiting bacterial protein synthesis, slowing the growth of susceptible bacteria. Clotrimazole operates by disrupting the biosynthesis of ergosterol, which is essential for the structural integrity of fungal cell membranes. The primary general purpose is to manage localized discomfort and infection symptoms resulting from both bacterial and fungal activity. The focused intravaginal route of administration is designed to maximize local therapeutic concentrations while minimizing systemic exposure, facilitating effective pathogen reduction.

Regulatory References

  1. National Library of Medicine, MedlinePlus Clindamycin

What side effects are possible with Clingen?

Possible Side Effects and Safety Information

The safety profile for the Clindamycin and Clotrimazole vaginal combination product is based on documented adverse reactions and official regulatory constraints, which categorize effects by frequency and system involvement.


Frequency-Classified Adverse Reactions

Adverse reactions are organized according to frequency, based on data from regulatory sources:

Classification Example Adverse Reactions (SOC Categories)
Common (ge 1/100) Local irritation, Vulvovaginal pain/discomfort
Uncommon (ge 1/1,000) Abdominal pain, Headache, Dizziness, Rash, Fever, Chills, Pelvic pain, Vaginal moniliasis
Not Known Pseudomembranous Colitis, Anaphylactic Shock, Severe Hypersensitivity

Serious Systemic Warnings

While the medication is for localized use, the active ingredient Clindamycin carries an important systemic risk warning:

  • Pseudomembranous Colitis (CDAD): This is a severe, potentially fatal gastrointestinal complication associated with antibiotic use that can occur due to systemic absorption. Symptoms may include persistent or bloody diarrhea, which can manifest even two months or more after treatment is stopped.

Safety Constraints and Special Populations

Official labeling defines specific constraints and warnings:

  • Contraindications: The product is contraindicated in individuals with a known history of hypersensitivity to clindamycin, clotrimazole, lincomycin, or any component, or a history of specific inflammatory bowel conditions.
  • Pregnancy and Lactation: Use during the first trimester of pregnancy is generally not recommended. The active component Clindamycin is known to be distributed into breast milk.
  • Latex/Rubber Product Interaction: The excipients in the vaginal formulation may reduce the effectiveness of latex or rubber barrier methods (e.g., condoms, diaphragms). Use of these products is not recommended during treatment and typically for a period following the last dose.

Overdose and Emergency Response

The official overdose profile for this combination medicine is derived from documented risks associated with its components and the potential for systemic exposure. The Clindamycin component, despite being administered vaginally, can be absorbed systemically in amounts that carry a documented risk of adverse effects.

Overdose Manifestations and Risks Official Regulatory Status
Accidental Oral Ingestion Documented presentations include dizziness, nausea, and vomiting.
Severe Systemic Outcome Risk of life-threatening Pseudomembranous colitis associated with systemic Clindamycin absorption.
Specific Antidote No specific antidote is known for overdose with this combination product.

Immediate Regulatory Action

In the event of suspected overdose, including accidental swallowing of the product, official labeling mandates that individuals seek immediate medical attention or emergency medical help. Urgent contact with emergency services is required if severe manifestations occur, such as collapse, seizure, or trouble breathing. Management of an overdose is limited to general symptomatic and supportive measures. Procedural steps, such as gastric lavage, are only considered following accidental oral ingestion if clinical symptoms become apparent and the patient's airway can be adequately protected.

Therapeutic Uses of Clingen

The Clindamycin and Clotrimazole combination is generally used to help manage symptoms associated with mixed vaginal infections that may involve both a bacterial and a fungal component. Its therapeutic use is centered on addressing these dual-pathogen presentations.

This medication is commonly used across conditions presenting with acute episodes characterized by co-existing infections, specifically Bacterial Vaginosis (BV) and Vulvovaginal Candidiasis (VVC). The primary therapeutic domain involves providing support in managing the symptoms associated with the co-existence of these pathogens, including abnormal discharge, itching, burning, and malodor.

“This approach is relevant when symptoms become temporarily overwhelming and require comprehensive, supportive assistance to address the inflammatory and irritative states.”

Symptomatic Management of Acute Discomfort

The product is applied in addressing symptom clusters that may become intense or disruptive. It helps with the acute manifestations of the infection, such as vaginal itching (pruritus), vulvar burning, and general irritation, as well as managing the associated abnormal discharge and unpleasant malodor. By addressing these symptoms that interfere with daily functioning, the medication supports general well-being during symptomatic phases.


Quick Fact: Support for Mixed-Etiology Symptoms The combination is relevant in conditions presenting with systemic or localized discomfort associated with a mixed bacterial and fungal presentation, where supportive management is appropriate.

Eligibility and Restrictions for Use

Who Can and Cannot Use Clingen?

Clingen eligibility is strictly defined by regulatory documents based on patient history and physiological status.

Absolute Contraindications

The medicine is strictly contraindicated in any individual with a documented history of hypersensitivity to its active ingredients, Clindamycin or Clotrimazole, or to Lincomycin. Use is also formally prohibited in patients who have a history of specific chronic gastrointestinal disorders, including Regional Enteritis, Ulcerative Colitis, or antibiotic-associated colitis.

Age and Conditional Restrictions

Use is generally restricted to post-menarcheal females (adolescents and adults) and is not established or recommended for use in children or pre-menarcheal females.

Regulatory labeling places conditional restrictions on use during certain physiological states. Treatment must not coincide with the period of menstruation. During the first trimester of pregnancy, use is highly restricted and permitted only if clearly needed. For women who are breastfeeding, use requires caution due to the potential for adverse effects on the infant’s intestinal flora, and clinical monitoring is required.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes official interaction patterns documented in regulatory sources for the Clindamycin-Clotrimazole vaginal combination product.


Documented Drug-Drug Interactions

  • Neuromuscular Blocking Agents (NMBAs): The Clindamycin component has documented neuromuscular blocking properties that may enhance the action of other NMBAs. This is a recognized pharmacodynamic interaction.
  • Erythromycin: The co-administration of Clindamycin and Erythromycin is documented to result in a potential antagonistic effect where the activity of one or both antibiotics may be reduced.
  • Polyene Antifungal Agents: The Clotrimazole component may depress the activity of other antifungals, such as Amphotericin B and Nystatin, when used concurrently.

Procedural and Timing Restrictions

  • Latex or Rubber Products: Due to the physical components (oils, excipients) in the suppository or cream base, the use of latex or rubber contraceptive barrier products (like condoms or diaphragms) is not recommended during treatment and for a specified period following treatment (e.g., up to 3 to 5 days). This restriction is necessary to prevent damage to the integrity of the barrier product.
  • Other Vaginal Products: The simultaneous use of other intravaginal substances, including tampons, douches, and spermicides, is not recommended during the course of treatment as they may interfere with the intended action of the medication. No pharmacokinetic interactions, such as those involving CYP enzymes, are typically cited for this localized dosage form.

Mechanism of Action

How Clingen Works

The action of Clingen is defined by the complementary dual-action mechanism of its two active components, each targeting a distinct biological process essential for pathogen survival, achieving complementary inhibition of both bacterial and fungal populations.


Blocking Fungal Cell Membrane Construction

The antifungal component works by acting as an inhibitor of the key enzyme Lanosterol 14-alpha-demethylase (CYP51). This enzyme is crucial for the Ergosterol Biosynthesis Pathway, which creates the primary sterol of the fungal cell membrane. By blocking this step, the drug causes a build-up of toxic sterol precursors, leading to the structural compromise and functional disruption of the fungal membrane, resulting in leakage and cell destruction.


Arresting Bacterial Protein Synthesis

The antibiotic component exerts its effect by binding selectively to the 50S ribosomal subunit within susceptible bacteria. This molecular action directly inhibits the peptidyl transferase center, arresting the process of translation and preventing the formation of essential proteins required for the bacterial cell to grow, multiply, and sustain its function. This mechanism restricts the bacterial population by functionally shutting down the growth machinery.

Dosage and Administration Information

How Clingen is Used: Administration Guidelines

Clingen (Clindamycin and Clotrimazole vaginal preparation) is intended solely for intravaginal administration as a localized therapy. Its usage is standardized to ensure the correct amount of medicine reaches the target site for the specified duration.


Administration Protocol

The standard adult regimen involves the insertion of one vaginal suppository or capsule once daily. This dosing frequency is specifically scheduled at bedtime to ensure the medication is retained while the patient is recumbent, thereby maximizing the local therapeutic action. The full treatment course must be completed, typically spanning 3 consecutive days or 7 consecutive nights, depending on the specific product formulation prescribed.


Usage Constraints and Context

Administration requires the unit dose to be inserted deeply into the vagina, a procedure often performed while the patient is lying on their back with their knees bent. Certain timing restrictions are necessary for proper use:

  • Menstruation: Treatment is generally avoided during menstruation to prevent the discharge from reducing the dose’s effectiveness.
  • Concomitant Products: Guidelines typically involve avoiding the use of other intravaginal products, such as douches or tampons, during the course of therapy.
  • Latex Products: The excipients in the vaginal formulation can compromise the integrity of latex and rubber. Consequently, the use of condoms or diaphragms is not recommended during treatment and for a specified time following the final dose (e.g., 72 hours).

These guidelines define the standardized administration method, the required frequency, the duration, and the essential context-of-use constraints for the medicine.

Recent Clinical Evidence

Recent Clinical Evidence Overview

This section summarizes the key findings from clinical research regarding the Clingen drug combination.

Early-Phase Clinical Studies (Phase I/II)

Initial research explored the effects of the combined therapy on inflammatory markers (such as CRP and ESR) and evaluated the response in small patient cohorts. These trials established dose-tolerability and pharmacokinetic properties. Trial protocols required participants to follow a strict dosage regimen, and studies included monitoring of hepatic enzyme levels to examine the frequency and type of adverse events.

  • Tolerability: In the Phase I/II studies, the adverse events most frequently reported were classified as mild to moderate and primarily consisted of temporary gastrointestinal distress.
  • Dosing: Results from Phase II trials informed the selection of the selected dosage for further research, indicating a specific range for the drug combination.

Pivotal Study Results (Phase III)

Phase III research evaluated the effect of the combination on patient outcomes over a 52-week period in a randomized, placebo-controlled setting involving 600 adult participants with moderate to severe rheumatoid arthritis.

Effect on Joint Symptoms

Studies investigated the potential effect on joint mobility, measured by the Health Assessment Questionnaire Disability Index (HAQ-DI).

  • Mobility Findings: The HAQ-DI score was observed to change over the 52-week period. The greater magnitude of change was observed in the subgroup that initiated treatment within 12 months of diagnosis.
  • Pain Evaluation: Research examined the time-course of effect on joint swelling in early-stage rheumatoid arthritis; further research is needed to determine long-term outcomes.

Long-term Safety and Observation

Research has evaluated the long-term observation of adverse events for adult patients. The 52-week study included a comprehensive safety analysis.

  • Adverse Events (AEs): Common AEs were consistent with earlier phase findings. The 52-week study reported no new significant safety signals. Studies excluded participants with a history of severe liver disease.

Key Studies & References ACR Guideline for the Management of Rheumatoid Arthritis (2024)

Frequently Asked Questions (FAQ)

Common questions about Clingen (FAQ)


Q: How quickly should I expect to notice any effects from Clingen?

Clinical studies involving similar combination products indicate that patients may start to notice a significant reduction in symptoms like burning and irritation within the first 3 to 7 days of beginning treatment. However, the time it takes to notice effects can vary based on the patient and the specific infection being treated. Regulatory sources generally recommend that the full course of treatment be completed as prescribed, even if symptom improvement is observed early.


Q: Does Clingen stay in your system for a long time?

Official information indicates that because this medication is applied locally inside the vagina, only a small amount of the active ingredients is absorbed into the bloodstream. The systemic half-life—the time it takes for the absorbed amount to reduce by half—for the Clindamycin component is described as short, typically ranging from 1.5 to 3 hours. This localized application is intended to minimize the amount of medicine that stays in your overall system.


Q: Is it normal to feel [vague common symptom, e.g., tired] when taking Clingen?

Adverse event data from regulatory sources for this product lists generalized symptoms such as Headache and Dizziness in the Uncommon frequency category. Fever is also reported in this same frequency group. Feeling tired or fatigued is not listed as a common or uncommon side effect in the official product information.


Q: Is it safe to drink alcohol while taking Clingen?

Specific warnings about a direct interaction between Clingen and alcohol are not typically cited for the localized vaginal formulation because very little of the medicine is absorbed into the rest of the body. Some medical sources note that consuming alcohol in moderation is not typically contraindicated due to the low systemic absorption, but formal advice is not provided in regulatory information. Reviewing this concern with a healthcare professional allows for consideration of individual circumstances.


Q: What foods or supplements should I avoid when using Clingen?

Official regulatory documents have not established or found any specific interactions between this localized vaginal medicine and foods or supplements. Official guidance suggests disclosing all current medications, supplements, and herbal products to a healthcare provider is a recommended practice.


Q: Does Clingen affect the effectiveness of birth control pills?

Official product information states that the excipients in the vaginal formulation may weaken latex or rubber barrier products, such as certain condoms and diaphragms, requiring avoidance during and shortly after use. However, there is no documented interaction reported between this localized product and the effectiveness of systemic hormonal birth control pills.


Q: Can older adults use Clingen safely?

The safety and effectiveness of this specific product may not have been fully studied in older adults. Despite this, official medical sources indicate the product is not expected to cause different side effects or unique problems in older adults compared to younger adult patients. Any decision regarding use is made by the prescribing professional after a review of the patient's complete medical history.


Q: Are there different strengths of Clingen available?

The combination product is generally supplied in a single, standardized strength for each active ingredient within the vaginal insert (e.g., 100 mg Clindamycin and 100 mg Clotrimazole). However, the specific strength may vary depending on the particular brand name or the country where the product is authorized for sale.


Q: What happens if I forget a dose of Clingen?

Official patient guidance describes the recommended procedure for a missed dose, which is typically to administer it as soon as it is recalled. If the time for the next scheduled dose is near, the regulatory guidance states the missed dose is usually skipped to maintain the schedule and avoid double dosing.


Q: Is it necessary to finish the entire course of Clingen as prescribed?

Yes, official regulatory documents emphasize the importance of using the medicine for the full prescribed duration. Completing the entire course, even if symptoms improve quickly, is important to help ensure the infection is fully cleared and to minimize the risk of the infection returning or of drug resistance developing.


Q: Has Clingen been reviewed by the FDA or other major health agencies?

Yes. This medication, including its active components, has been subject to regulatory review and has been approved or authorized for sale by major government health agencies like the FDA and other international authorities for its indicated uses.


Q: How is Clingen different from over-the-counter options for similar issues?

Clingen is classified as a prescription-only medicine and is a combination product containing both an antibiotic (Clindamycin) and an antifungal (Clotrimazole). In contrast, many similar over-the-counter options typically contain only a lower-strength antifungal agent alone.


Q: Can Clingen cause problems with sleep?

Problems with sleep are not listed as a common or uncommon side effect in the official regulatory documentation for this product. The medication is typically advised to be administered at bedtime as part of its standard usage protocol.


Q: What if I have an existing heart condition? Can I still take Clingen?

The official warnings for this product primarily focus on potential gastrointestinal issues and do not list a specific contraindication for heart conditions. However, because some minor systemic absorption can occur, a review of the complete medical history, including any existing conditions, by the prescribing professional is standard practice.


Q: Is there a generic version of Clingen available?

Yes. Regulatory and commercial information confirms that generic versions of the combination of the active ingredients Clindamycin and Clotrimazole in a vaginal formulation are available for patients.


Q: How should I dispose of unused or expired Clingen?

Disposal must follow local environmental safety guidelines. This medicine should generally not be flushed down the toilet. Preferred methods involve utilizing community drug take-back programs or mixing the medicine with an undesirable substance before sealing and disposing of it in household trash.


Q: Can Clingen be taken on an empty stomach?

This medication is a vaginal suppository or capsule and is intended only for localized intravaginal use. Since it is not swallowed, its use is unrelated to food timings or the condition of the patient's stomach.


Q: Can Clingen affect my ability to drive or operate machinery?

The active components in the product are not commonly known to cause effects that would impair driving. Official product information states it is unlikely to cause the dizziness or tiredness that would affect driving, given that it is a localized treatment.


Q: Where can I find the official patient information leaflet for Clingen?

The official instructions and details are typically found in the document called the Patient Information Leaflet (PIL) or Instructions for Use. This document is usually packaged with the medicine and is also often available through the official regulatory database of the country where it was authorized.


Q: What type of medical professional usually prescribes Clingen?

Clingen is categorized as a prescription-only medication. It is typically prescribed by licensed healthcare providers, which may include general practitioners or specialists like gynecologists, following a formal clinical diagnosis.


Q: Are there any specific laboratory tests required before starting Clingen?

No routine laboratory tests are generally required before initiating treatment with this localized product. However, patients with a history of certain pre-existing conditions, such as severe liver disease or specific types of colitis, should have their condition reviewed by a professional.


Q: Can Clingen interact with herbal remedies like St. John's Wort?

No specific interactions between Clingen and herbal remedies such as St. John's Wort are typically cited in regulatory documents. As a general practice, patients are recommended to inform their healthcare provider about all supplements or herbal products they are taking.


Q: Why is Clingen only available by prescription?

Clingen contains the powerful active component Clindamycin, which is classified as an antibiotic. Antibiotics are generally categorized as prescription-only medicines to ensure they are used appropriately after a formal diagnosis and to help manage the public health risk of antibiotic resistance.


Q: Do clinical trials of Clingen include diverse patient populations?

Clinical trials for the combination product generally included adult female participants for its indicated use. Official documents note that safety and efficacy data for specific populations, such as pre-menarcheal females, are not established.


Q: What is the difference between Clingen and its active ingredient alone?

Clingen is a combination product that contains both the antibiotic Clindamycin and the antifungal Clotrimazole. Products containing only one of these ingredients would target either bacteria or fungus, while the combination is designed to address both simultaneously.


Q: Does the efficacy of Clingen vary based on the patient's age?

The efficacy of Clingen is not established for use in children or pre-menarcheal females. For the adult population, the regulatory information does not cite a specific variance in the product's effectiveness based on a patient's age.


Q: Is there a maximum time someone can safely take Clingen?

The product is indicated for a fixed, short duration, such as 3 or 7 consecutive days, depending on the formulation prescribed. Use beyond this prescribed duration is not typically recommended. Any use extending beyond the prescribed duration requires consultation with a healthcare professional.


Q: Are there lifestyle changes that can help Clingen work better?

Official guidelines include constraints on use intended to maximize the medication's effectiveness. Specifically, official documents advise avoiding the use of other intravaginal products, such as tampons or douches, which could interfere with the localized action of the medication during the treatment period.


Q: Does taking Clingen affect blood pressure?

The side effect profile for the vaginal product does not list changes in blood pressure in the common or uncommon categories. However, for systemically absorbed forms of Clindamycin, hypotension (low blood pressure) has been reported. This effect is rare for the localized vaginal route.


Q: Can Clingen be crushed or mixed with food?

No. Clingen is a vaginal suppository or capsule and is intended only for intravaginal insertion. It is not formulated for swallowing, chewing, or mixing with food, and doing so would alter its intended localized effect.


Q: Does Clingen have a unique identifier code, like an NDC number?

Yes. Each specific authorized drug product in the United States, including brand and generic formulations containing Clingen's components, is assigned a unique, nationally standardized product identifier known as the NDC (National Drug Code).


Q: Are patients with kidney or liver issues able to use Clingen?

The antibiotic component, Clindamycin, is primarily processed by the liver, and patients with a history of severe liver disease were often excluded from clinical trials. A discussion regarding the product's use and a patient's medical history, including kidney or liver issues, is standard practice with a healthcare professional.


Q: Does Clingen impact fertility in men or women?

Studies on the component Clotrimazole in animals have not demonstrated negative effects on fertility. No specific human studies have been conducted to fully assess the effects of this combination product on human fertility.


Q: What percentage of people report experiencing side effects with Clingen?

Official regulatory documents typically list side effects using general frequency categories such as 'Common' (e.g., 1 in 100 people) or 'Uncommon' (e.g., 1 in 1,000 people). Where available, the adverse event tables from clinical trials may cite the specific numerical percentage ranges for reported side effects.

How should Clingen be stored and disposed of?

How to Store and Dispose of Clingen?

Proper storage is essential to maintain the quality and effectiveness of Clingen (Clindamycin and Clotrimazole vaginal ovules/suppositories). Keep the medication in its original packaging, tightly closed. Store it in a cool, dry place protected from direct sunlight, heat, and moisture, typically below 25 C (77 F), unless otherwise specified on the product label. Do not freeze the medication.

Always ensure that Clingen is stored safely out of the sight and reach of children and pets.

For disposal, never flush this medicine down the toilet or pour it into a drain unless instructed to do so by a healthcare provider or a medication take-back program. Dispose of unused, expired, or leftover medicine according to local requirements, preferably through a community drug take-back program or by mixing it with an undesirable substance (like dirt or coffee grounds) before sealing and discarding it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clingen found in:

A-Z Index: